CLAIMS

1. A crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine mono succinate salt.

2. The crystalline form of Claim 1, characterized by one of the following: 1) a powder X-ray diffraction pattern comprising peaks at 2θ values of: 19.7, 24.3, 9.3 and 16.6 ± 0.2 °2θ; (2) a Raman spectrum comprising wavenumber values of: 1041 and 1217 cm^{-1} ±2 cm^{-1}; or (3) a ^{13}C solid state NMR spectrum comprising a resonance value of: 179.0 ppm ± 0.2 ppm.

3. The crystalline form of Claim 1 or 2, characterized by two of the following: 1) a powder X-ray diffraction pattern comprising peaks at 2θ values of: 19.7, 24.3, 9.3 and 16.6 ± 0.2 °2θ; (2) a Raman spectrum comprising wavenumber values of: 1041 and 1217 cm^{-1} ±2 cm^{-1}; or (3) a ^{13}C solid state NMR spectrum comprising a resonance value of: 179.0 ppm ± 0.2 ppm.

4. The crystalline form of any one of Claims 1 to 3, characterized by: 1) a powder X-ray diffraction pattern comprising peaks at 2θ values of: 19.7, 24.3, 9.3 and 16.6 ± 0.2 °2θ; (2) a Raman spectrum comprising wavenumber values of: 1041 and 1217 cm^{-1} ±2 cm^{-1}; and (3) a ^{13}C solid state NMR spectrum comprising a resonance value of: 179.0 ppm ± 0.2 ppm.

5. The crystalline form of any one of Claims 1 to 4 having a powder X-ray diffraction pattern comprising peaks at 2θ values of: 19.7, 24.3, 9.3 and 16.6 ± 0.2 °2θ.

6. The crystalline form of any one of Claims 1 to 5, having a powder X-ray diffraction pattern further comprising a peak at the 2θ value of: 9.0 ± 0.2 °2θ.

7. The crystalline form of any one of Claims 1 to 6, having a powder X-ray diffraction pattern further comprising a peak at the 2θ value of: 28.0 ± 0.2 °2θ.

8. The crystalline form of any one of Claims 1 to 7, having a powder X-ray diffraction pattern further comprising a peak at the 2θ value of: 18.8 ± 0.2 °2θ.

9. The crystalline form of any one of Claims 1 to 8, having a powder X-ray diffraction pattern further comprising a peak at the 2θ value of: 15.7 ± 0.2 °2θ.

10. The crystalline form of any one of Claims 1 to 9, having a powder X-ray diffraction pattern further comprising a peak at the 2θ value of: 12.1 ± 0.2 °2θ.

11. The crystalline form of any one of Claims 1 to 10, having a Raman spectrum comprising wavenumber (cm^{-1}) values of: 1041 and 1217 cm^{-1} ± 2 cm^{-1}.

12. The crystalline form of Claim 11, having a Raman spectrum comprising wavenumber (cm^{-1}) values of: 1026 and 1555 cm^{-1} ± 2 cm^{-1}.

13. The crystalline form of any one of Claims 1 to 12, having a ^{13}C solid state NMR spectrum comprising a resonance (ppm) value of: 179.0 ppm ± 0.2 ppm.

14. The crystalline form of any one of Claims 1 to 13, having a ^{13}C solid state NMR spectrum comprising a resonance (ppm) value of: 46.4 ppm ± 0.2 ppm.

15. The crystalline form of any one of Claims 1 to 14, having a ^{13}C solid state NMR spectrum comprising a resonance (ppm) value of: 38.0 ppm ± 0.2 ppm.

16. The crystalline form of any one of Claims 1 to 15, having a ^{13}C solid state NMR spectrum comprising a resonance (ppm) value of: 141.7 ppm ± 0.2 ppm.

17. The crystalline form of any one of Claims 13 to 16, having a ^{13}C solid state NMR spectrum comprising a resonance (ppm) value of: 27.1 ppm ± 0.2 ppm.

18. The crystalline form of any one of Claims 1 to 17 which is substantially pure and free of alternative forms.

19. A pharmaceutical composition comprising the crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine mono succinate salt according to any one of Claims 1 to 18, and at least one pharmaceutically acceptable excipient.

20. The crystalline form of any one of Claims 1 to 18 for use as a medicament.

21. The crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine mono succinate salt according to any one of Claims 1 to 18 for use in treating abnormal cell growth.

22. Use of the crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine mono succinate salt according to any one of Claims 1 to 18 in the manufacture of a medicament for the treatment of abnormal cell growth.

23. The compound or use of Claim 21 or 22, wherein the abnormal cell growth is cancer.

24. The compound or use of Claim 23, wherein the cancer is selected from the group consisting of melanoma, juvenile myelomoncytic leukemias, neuroblastoma, Philadelphia chromosome positive chronic myeloid leukemia, Philadelphia chromosome positive acute lymphoblastic leukemias, acute myeloid leukemias, myeloproliferative neoplasms (such as Polycythemia Vera, Essential Thrombocythemia and Primary Myelofibrosis), breast cancer, lung cancer, liver cancer, colorectal cancer, esophageal cancer, gastric cancer, squamous-cell carcinoma of the head and neck, glioblastoma, anaplastic large-cell lymphoma, thyroid carcinoma, and spitzoid neoplasms.

25. The compound or use of Claim 23, wherein the cancer is selected from the group consisting of non-small cell lung cancer, colon cancer, esophageal cancer, rectal cancer, juvenile myelomonocytic leukemia, breast cancer, melanoma, and pancreatic cancer.

26. The compound or use of Claim 23, wherein the cancer is selected from the group consisting of ALK-positive NSCLC, ROS1-positive NSCLC, BRAF V600E mutation colorectal cancer, RAS-mutant solid tumors, NF1-mutant solid tumors, and BRAF class 3-mutant solid tumors.

27. The compound or use of Claim 26, wherein the cancer is ALK-positive NSCLC.

28. The compound or use of Claim 27, wherein the cancer being treated is with prior lorlatinib treatment and with prior platinum-based chemotherapy treatment.

29. The compound or use of Claim 27, wherein the cancer being treated is with prior lorlatinib treatment and without prior platinum-based chemotherapy treatment.

30. The compound or use of Claim 27, wherein the cancer being treated is without prior lorlatinib treatment.

31. The compound or use of Claim 26, wherein the cancer is BRAF V600E mutation colorectal cancer.

32. The compound or use of Claim 31, wherein the cancer being treated is resistant to BRAF inhibitor plus epidermal growth factor receptor inhibitor treatment.

33. The compound or use of Claim 31, wherein the cancer being treated is refractory BRAFi plus EGFRi treatment.

34. The compound or use of Claim 31, wherein the cancer being treated is with no prior BRAFi plus EGFRi treatment.

35. The compound or use of Claim 26, wherein the cancer is RAS-mutant solid tumors.

36. The compound or use of Claim 35, wherein the cancer being treated has received prior standard of care.

37. The compound or use of Claim 26, wherein the cancer is NF1-mutant solid tumors.

38. The compound or use of Claim 37, wherein the cancer being treated has received prior standard of care.

39. The compound or use of Claim 26, wherein the cancer is BRAF class 3-mutant solid tumors.

40. The compound or use of Claim 39, wherein the BRAF class 3-mutation is selected from one or more of the following amino acid substitutions in human BRAF: D287H; P367R; V459L; G466V; G466E; G466A; S467L; G469E; N581S; N581I; D594N; D594G; D594A; D594H; F595L; G596D; G596R and A762E.

41. The compound or use of Claim 39 or 40, wherein the cancer being treated has received prior standard of care.

42. The compound or use of Claim 23, wherein the cancer is a KRAS mutation cancer.

43. The compound or use of Claim 42, wherein the cancer is selected from a KRASG12A mutation, a KRASG12C mutation, a KRASG12D mutation, a KRASG12F mutation, a KRASG12I mutation, a KRASG12L mutation, a KRASG12R mutation, a KRASG12S mutation, a KRASG12V mutation, and a KRASG12Y mutation.

44. The compound or use of any one of Claims 21 to 43, wherein the compound according to any one of Claims 1 to 18 is to be used in combination with an additional therapeutic compound.

45. The compound or use of Claim 44, wherein the additional therapeutic is selected from the group consisting of lorlatinib, binimietinib, cetuximab, and encorafenib.

46. The compound or use of Claim 45, wherein the additional therapeutic compound is lorlatinib.

47. The compound or use of Claim 45, wherein the additional therapeutic compound is binimetinib.

48. The compound or use of Claim 45, wherein the additional therapeutic compound is cetuximab and encorafenib.